laquinimod

An oral drug for multiple sclerosis, called laquinimod, failed to reduce relapses of the debilitating disease compared to a placebo, marking a setback for the experimental drug.

Mixed Results for Oral Multiple-Sclerosis Drug Thomas Gryta 2011

The study involved 1,106 people that took either laquinimod or a placebo on a daily basis for two years.

Biogen MS Pill Shows Promise in Clinical Trial Thomas Gryta 2011

The group wasn't designed for direct comparison to the other groups in the study, but showed that Avonex was more effective than laquinimod at cutting relapses and Avonex was less effective than the pill at delaying disability progression.

Mixed Results for Oral Multiple-Sclerosis Drug Thomas Gryta 2011

However, Teva Pharmaceutical Industries Ltd. said Monday that patients in the laquinimod and placebo groups had dissimilar MRI brain scans at the beginning of the trial.

Mixed Results for Oral Multiple-Sclerosis Drug Thomas Gryta 2011

However, its plans to bring a new MS treatment to market, the experimental drug laquinimod, are on hold.

Teva Adjusts Outlook on U.S. Weakness Peter Loftus 2011

Recent data from large clinical trials of other drugs being developed, including Biogen Idec's BG-12, Teva Pharmaceutical's laquinimod, and teriflunomide, from Sanofi-Aventis SA, show they are also effective at controlling MS flare-ups and slowing the progression of disability from the disease.

Pills Offer Easier Way to Treat MS Thomas Gryta 2011

Last month, the company reported positive data on its oral multiple-sclerosis treatment laquinimod, developed by Sweden-based Active Biotech, which may provide a foothold in the emerging market for oral multiple-sclerosis treatments while also helping dilute the dependence on Copaxone's profits.

Teva Buys Japanese Generics Maker Taiyo Sten Stovall 2011

Monday, Teva released data from a major study showing that its oral treatment for MS, laquinimod, significantly reduced the number of relapses of the disease, while cutting the progression of resulting disability.

Biogen MS Pill Shows Promise in Clinical Trial Thomas Gryta 2011

Smaller reductions in flare-ups were seen in trials with patients using laquinimod (23%) and teriflunomide (31%).

Pills Offer Easier Way to Treat MS Thomas Gryta 2011

Teva Pharmaceutical Industries and Active Biotech said today a two-year, Phase 3 study of its multiple sclerosis drug laquinimod showed a statistically significant, 23% reduction in the rate of relapse, which was the primary endpoint.

Teva MS Drug Clears Key Hurdle 2011